Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 9/20 | 0.41 |
| ▸ | CHUK | O15111 | 9/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 4/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412830 | 0.89 | IKBKB (0.43) | IKBKBCHUKNEK1ROCK1CYP2C9 | |
| SCHEMBL3613975 | 0.84 | IKBKB (0.42) | IKBKBCHUKNEK1ROCK1CYP2C9 | |
| SCHEMBL13013344 | 0.83 | IKBKB (0.42) | ALOX5APFEN1IKBKBCHUKNEK1 | |
| SCHEMBL3415657 | 0.83 | IKBKB (0.51) | ALOX5APFEN1IKBKBCHUKNEK1 | |
| SCHEMBL4317149 | 0.81 | IKBKB (0.40) | IKBKBCHUKNEK1ROCK1 | |
| SCHEMBL13013877 | 0.80 | IKBKB (0.40) | ALOX5APFEN1IKBKBCHUKNEK1 | |
| SCHEMBL30135028 | 0.79 | EGFR (0.43) | — | |
| SCHEMBL13241039 | 0.79 | P2RY14 (0.43) | ALOX5APFEN1 | |
| SCHEMBL13013183 | 0.78 | IKBKB (0.61) | ALOX5APFEN1IKBKBCHUKNEK1 | |
| SCHEMBL13507592 | 0.78 | ALOX5AP (0.42) | ALOX5APFEN1IKBKBCHUKNEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008034860-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | ALOX5AP 2957/4885FEN1 2021/4885IKBKB 4/4885 |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | PLK2, PDXK, MAP4K2 | ALOX5AP 4216/4885FEN1 1525/4885IKBKB 428/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | ALOX5AP 2957/4885FEN1 2021/4885IKBKB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.